Larkspur Health Acquisition Corp. announces business combination with ZyVersa Therapeutics and $7M private placement

ZyVersa Therapeutics, Inc.

SPAC Larkspur (LSPR) entered into Business Combination Agreement with ZyVersa Therapeutics, a clinical-stage biopharma targeting renal and inflammatory diseases.
Private placement of approximately $7.0M in Convertible Preferred shares and warrants to fund the deal, subject to additional interim financing and Nasdaq listing.
Closing deadline set for December 15, 2022; transaction requires shareholder approval and other customary conditions.
ZyVersa will survive as a wholly owned subsidiary; combined company expected to be named ZyVersa Therapeutics.
Company warrants and options assumed and converted into SPAC equity; key shareholders enter lock-up and support agreements.

item 1.01 item 3.02 item 5.03 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.